MARKET

ATYR

ATYR

Atyr Pharma Inc
NASDAQ
1.830
-0.020
-1.08%
After Hours: 1.880 +0.05 +2.73% 16:52 06/14 EDT
OPEN
1.830
PREV CLOSE
1.850
HIGH
1.910
LOW
1.820
VOLUME
141.80K
TURNOVER
0
52 WEEK HIGH
2.450
52 WEEK LOW
1.080
MARKET CAP
126.29M
P/E (TTM)
-2.0270
1D
5D
1M
3M
1Y
5Y
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023
Investorplace · 6d ago
Weekly Report: what happened at ATYR last week (0603-0607)?
Weekly Report · 6d ago
*News On aTyr Pharma Inc. (LIFE) Now Under ATYR
Dow Jones · 06/05 21:08
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change From "LIFE" To "ATYR", Effective At The Market Open On June 5, 2024
ATyr Pharma, Inc. Will be changing its ticker symbol from "LIFE" to "ATYR" effective June 5, 2024. The Company's common stock will trade on the Nasdaq Capital Market under the new symbol. ATyr is a clinical stage biotechnology company.
Benzinga · 06/03 12:27
aTyr Pharma announces Nasdaq ticker symbol change to “ATYR”
ATyr Pharma announces Nasdaq ticker symbol change to “ATYR” effective June 5, 2024. Company's common stock will trade on the Nasdaq Capital Market under the new symbol ‘ATYR.’ aTyr is developing a lead therapeutic candidate, efzofitimod.
Seeking Alpha · 06/03 12:19
ATYR PHARMA ANNOUNCES NASDAQ STOCK TICKER SYMBOL CHANGE FROM “LIFE” TO “ATYR”
Reuters · 06/03 12:04
Weekly Report: what happened at LIFE last week (0527-0531)?
Weekly Report · 06/03 10:11
aTyr Pharma Stockholders Endorse Leadership and Progress
TipRanks · 05/30 07:13
More
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: ATYR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATYR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATYR stock methods without spending real money on the virtual paper trading platform.